Antidiabetic drug profile of COVID-19 patients with comorbid diabetes mellitus

IF 0.5 Q4 EDUCATION, SCIENTIFIC DISCIPLINES

Pharmacy Education Pub Date : 2023-10-10 DOI:10.46542/pe.2023.234.168172

Didik Hasmono, Samirah Samirah, Ni Putu Ayu Deviana Gayatri, Naning Ni’mawati, Halim Prihayau Jaya, Erwin Astha Triono

{"title":"Antidiabetic drug profile of COVID-19 patients with comorbid diabetes mellitus","authors":"Didik Hasmono, Samirah Samirah, Ni Putu Ayu Deviana Gayatri, Naning Ni’mawati, Halim Prihayau Jaya, Erwin Astha Triono","doi":"10.46542/pe.2023.234.168172","DOIUrl":null,"url":null,"abstract":"Background: Diabetes mellitus (DM) is a risk factor that can increase the severity and mortality of patients with COVID-19 infection. The use of antidiabetic drugs for diabetes mellitus patients with COVID-19 infection is very important to reduce these impacts. Objective: This study aimed to determine the antidiabetic drug profiles of COVID-19 patients with comorbid diabetes mellitus. Method: This study was an analytic cross-sectional electronic medical record data of patients diagnosed with COVID-19 and comorbid Diabetes Mellitus. It was carried out from May until December 2020. Result: A total of 106 patients were involved and different types of antidiabetic drugs were used i.e., glimepiride in 32 patients (31.13%), metformin in 18 patients (16.98%), combination of long-acting and rapid-acting insulin in 20 patients (18.87%), and combination of metformin and glimepiride in 18 patients (16.98%). Conclusion: The most commonly prescribed single antidiabetic therapy in patients with COVID-19 and comorbid diabetes mellitus was glimepiride, followed by glimepiride and metformin. The most common insulin therapy combination was long-acting and rapid-acting insulin.","PeriodicalId":19944,"journal":{"name":"Pharmacy Education","volume":"236 1","pages":"0"},"PeriodicalIF":0.5000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy Education","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46542/pe.2023.234.168172","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"EDUCATION, SCIENTIFIC DISCIPLINES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Diabetes mellitus (DM) is a risk factor that can increase the severity and mortality of patients with COVID-19 infection. The use of antidiabetic drugs for diabetes mellitus patients with COVID-19 infection is very important to reduce these impacts. Objective: This study aimed to determine the antidiabetic drug profiles of COVID-19 patients with comorbid diabetes mellitus. Method: This study was an analytic cross-sectional electronic medical record data of patients diagnosed with COVID-19 and comorbid Diabetes Mellitus. It was carried out from May until December 2020. Result: A total of 106 patients were involved and different types of antidiabetic drugs were used i.e., glimepiride in 32 patients (31.13%), metformin in 18 patients (16.98%), combination of long-acting and rapid-acting insulin in 20 patients (18.87%), and combination of metformin and glimepiride in 18 patients (16.98%). Conclusion: The most commonly prescribed single antidiabetic therapy in patients with COVID-19 and comorbid diabetes mellitus was glimepiride, followed by glimepiride and metformin. The most common insulin therapy combination was long-acting and rapid-acting insulin.

查看原文本刊更多论文

新冠肺炎合并糖尿病患者的降糖药物分析

背景:糖尿病(DM)是增加COVID-19感染患者严重程度和死亡率的危险因素。糖尿病合并COVID-19感染患者使用降糖药物对减少这些影响非常重要。目的:了解新冠肺炎合并糖尿病患者的降糖药物情况。方法:分析新冠肺炎合并糖尿病患者的横断面电子病历资料。该调查于2020年5月至12月进行。结果:共106例患者，使用不同类型的降糖药物，格列美脲32例(31.13%)，二甲双胍18例(16.98%)，长效与速效胰岛素联用20例(18.87%)，二甲双胍与格列美脲联用18例(16.98%)。结论:新型冠状病毒感染合并糖尿病患者最常用的单一降糖药物是格列美脲，其次是格列美脲和二甲双胍。最常见的胰岛素治疗组合是长效和速效胰岛素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacy Education EDUCATION, SCIENTIFIC DISCIPLINES-

CiteScore

0.80

自引率

20.00%

发文量

174

期刊介绍： Pharmacy Education journal provides a research, development and evaluation forum for communication between academic teachers, researchers and practitioners in professional and pharmacy education, with an emphasis on new and established teaching and learning methods, new curriculum and syllabus directions, educational outcomes, guidance on structuring courses and assessing achievement, and workforce development. It is a peer-reviewed online open access platform for the dissemination of new ideas in professional pharmacy education and workforce development. Pharmacy Education supports Open Access (OA): free, unrestricted online access to research outputs. Readers are able to access the Journal and individual published articles for free - there are no subscription fees or ''pay per view'' charges. Authors wishing to publish their work in Pharmacy Education do so without incurring any financial costs.